Advertisement
UK markets close in 7 hours 4 minutes
  • FTSE 100

    8,121.10
    +42.24 (+0.52%)
     
  • FTSE 250

    19,794.97
    +192.99 (+0.98%)
     
  • AIM

    755.68
    +2.56 (+0.34%)
     
  • GBP/EUR

    1.1653
    -0.0003 (-0.03%)
     
  • GBP/USD

    1.2521
    +0.0010 (+0.08%)
     
  • Bitcoin GBP

    51,426.29
    +268.33 (+0.52%)
     
  • CMC Crypto 200

    1,389.62
    -6.91 (-0.49%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • CRUDE OIL

    83.88
    +0.31 (+0.37%)
     
  • GOLD FUTURES

    2,359.50
    +17.00 (+0.73%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     
  • DAX

    18,045.28
    +128.00 (+0.71%)
     
  • CAC 40

    8,045.78
    +29.13 (+0.36%)
     

Stock Upgrades: Jazz Pharmaceuticals Shows Rising Relative Strength

Stock Upgrades: Jazz Pharmaceuticals Shows Rising Relative Strength

Jazz is doing well selling its specialty drugs including blockbuster narcolepsy drug Xyrem. The new rating means that Jazz has outperformed 81% of all stocks in the S&P 500 on key metrics over the past year. Jazz Pharmaceuticals holds the No. 3 rank among its peers in the Medical-Ethical Drugs industry group.